Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9580067 | 0.87 | HDAC4 (0.42) | ALDH1A1HPGDAOC3HDAC4HDAC2 | |
| SCHEMBL23745172 | 0.82 | PNMT (0.41) | ALDH1A1HPGDPGRPNMTACP3 | |
| SCHEMBL29364274 | 0.81 | HDAC4 (0.43) | ALDH1A1HPGDPGRHDAC4HDAC2 | |
| SCHEMBL30987496 | 0.81 | HDAC4 (0.43) | ALDH1A1HPGDPGRHDAC4HDAC2 | |
| SCHEMBL18316475 | 0.81 | HDAC4 (0.43) | ALDH1A1HPGDPGRHDAC4HDAC2 | |
| SCHEMBL180401 | 0.81 | HDAC4 (0.43) | ALDH1A1HPGDPGRHDAC4HDAC2 | |
| SCHEMBL5542593 | 0.80 | ALDH1A1 (0.39) | ALDH1A1HPGDPGRPNMTACP3 | |
| SCHEMBL3233190 | 0.80 | ACP3 (0.41) | ALDH1A1HPGDACP3AOC3KMT2A | |
| SCHEMBL17691229 | 0.79 | PNMT (0.44) | ALDH1A1HPGDPGRPNMTACP3 | |
| SCHEMBL19361662 | 0.79 | AOC3 (0.38) | ALDH1A1HPGDPGRPNMTACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| CN-1441781-A | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AG (SE) | 2003-09-10 | — | — | CN | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | ALDH1A1 305/4885HPGD 189/4885PGR 1576/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | ALDH1A1 452/4885HPGD 158/4885PGR 2080/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | ALDH1A1 305/4885HPGD 189/4885PGR 1576/4885 |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | ALDH1A1 690/4885HPGD 256/4885PGR 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.